Most material SEC filings — October 8, 2026

Chief Executive Officer Huang Jack Jiajia (COE) bought 2.8M shares (~$32.3M) on the open market (98% of holdings). Open-market insider purchase — historically a bullish signal.

Drilling Tools International Corporation (via subsidiary Casing Technologies Group Limited) agreed to acquire 100% of Saltire Energy Limited (1,240 shares) and Foxley Energy Limited (100 shares) for £60,289,856.60 cash plus loan notes and DTI Common Stock. Closing targeted January 5, 2027 or later, subject to financing, regulatory approvals, and shareholder vote. Material consideration includes earnout adjustments, leakage clawbacks, and tax liabilities.

Crescent Energy announced a definitive agreement to acquire Eagle Ford oil and gas assets from Devon Energy for approximately $3.85 billion net purchase price. The acquisition includes ~68 Mboe/d of net production and 600+ Tier 1 net locations in the Karnes Trough, expected to close Q4 2026 or early 2027. Financing will combine cash on hand with debt and equity as appropriate; approximately $140 million in annual synergies identified across drilling, completion, LOE, and marketing.

On July 21, 2026, NOVAGOLD and Paulson Advisers LLC signed definitive agreements whereby NOVAGOLD will acquire Paulson's 40% ownership interest in Donlin Gold LLC in an all-share transaction, increasing NOVAGOLD's stake from 60% to 100%. The deal is expected to close by year-end 2026 (conditional on shareholder approval, court approval, and regulatory approvals). Simultaneously, Endeavour Financial and Macquarie Capital were appointed to advise on project financing; NOVAGOLD holds $343.4 million in cash and term deposits as of August 31, 2026.

AquaBounty Technologies has executed conversion agreements for Series A and Series B Convertible Preferred Stock. Series A converts at $0.9129/share with liquidation value of $18.2580/share; Series B converts at $1.03/share with liquidation value of $20.60/share. Both convert automatically by October 30, 2026 or upon registration statement effectiveness. Specific share counts and holder identities are blank in template. Company must file Form S-3 registration statement and maintain effectiveness for resales; conversion terms include registration rights and indemnification provisions.

On October 8, 2026, NN Inc completed redemption of all 18,400 outstanding shares of Series D Perpetual Preferred Stock (par $0.01/share) for approximately $30.7 million, funded by a $53.1 million PIPE private placement closed October 5, 2026. The company secured a $5.0 million incentive from the sole holder, reducing the stated security value of $35.7 million to $30.7 million paid. This eliminates all preferred equity from the balance sheet and eliminates all holder rights associated with the security.

PowerCompute applied 267.4 Bitcoin in September 2026 to fully repay its $22.45M Arch credit facility (principal plus accrued interest), reducing total secured debt from $23.70M to $1.25M and releasing all pledged Bitcoin collateral. Bitcoin holdings fell from 323.02 BTC (August) to 63.7 BTC (September), valued at ~$5.3M. The company mined 8.1 BTC in September (+37% YoY, +2.7% MoM) and generated $89K in energy sales that month ($312K for Q3).

Viatris Inc. (via wholly owned subsidiary Peach Purchaser Sub Inc.) agreed on October 8, 2026 to acquire Pacira BioSciences, Inc. through a two-step transaction: a cash tender offer at $36.50 per share followed by a merger. As of October 7, 2026, Pacira had 39,912,226 shares outstanding (excluding 9,018,591 treasury shares). The offer price of $36.50 per share represents the sole consideration; equity awards (options, RSUs, PSUs) convert to cash at the offer price, and the company's $287.5M convertible notes are addressed separately. Viatris committed sufficient funds without financing contingency; the transaction is expected to close shortly after tender offer acceptance.

Hallador Power Company executed a 6-year capacity and energy agreement with an investment-grade MISO Zone 6 utility for Merom Generating Station (June 2029–May 2035). The deal includes ~$271M in capacity revenue and ~$422M in energy revenue (total ~$693M over term), priced at $80+/MWh—the company's highest capacity price to date, 20%+ above March 2026 contract. This raises total forward sales to $3B at segment level, with ~95% of Merom's accredited capacity contracted through 2035 and ~67% for 2036–2040.

Byrna Technologies reported Q3 2026 net revenue of $15.3M (down 46% from $28.2M in Q3 2025), driven by e-commerce decline and slower dealer/chain store reorder activity following prior-year restocking. Net loss was $2.9M versus net income of $2.2M in Q3 2025. The company completed the acquisition of HERO Defense Systems, LLC; onboarded 50+ influencers (3.8M combined followers); transitioned ammunition production to outsourced model (improving margins ~1,200 bps); and appointed new executives (Jim White, SVP Retail; Nate Secor, SVP Brand/Marketing) and board members (Rose Lopez Keravuori, Dr. Matthew McBrady). Cash stood at $8.4M; inventory at $30.0M; adjusted EBITDA was negative $1.4M versus positive $4.1M year-ago.

Nova Minerals announced arrival of all key antimony processing equipment at Port MacKenzie, Alaska on October 6, 2026, including ball mills, jaw crusher, and hydraulic filter presses. Construction of the antimony processing facility will commence following final permits. The $43.4 million U.S. Department of War-funded project targets first antimony production in 2027, with the company also completing an 8,000m drilling program at the Estelle gold project in Alaska.

Editas Medicine received Human Research Ethics Committee (HREC) approval and completed Clinical Trial Notification (CTN) with Australia's Therapeutic Goods Administration (TGA) to initiate the Phase 1/2 Strive trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia. The company expects to begin patient dosing in 2026 and report initial safety/tolerability data in Q1 2027. Preclinical data showing ~90% LDL-C reduction sustained over 10 months will be presented at AHA Scientific Sessions November 6-9, 2026; trial enrollment planned across five sites in Australia and New Zealand.

AngioDynamics appointed Eric Honroth as President and CEO effective November 2, 2026, with a $735,000 annual base salary, 95% target bonus, and sign-on inducements totaling $800,000 (cash bonus $350,000 + RSU equity buyout $450,000) plus a 350% base salary inducement award. Outgoing CEO Jim Clemmer retires and transitions to a consulting role at $30,000/month for 12 months. The company has no outstanding debt and operates with strong balance sheet momentum.

Hyperfine reported preliminary Q3 2026 revenue of approximately $6.0 million, representing 53% sequential growth from Q2 2026's $3.9 million and 66% year-over-year growth in nine-month 2026 revenue of $13.8 million. Net cash burn improved 29% sequentially to $5.6 million in Q3, and Q3 revenue exceeded cash burn for the first time. The company reaffirmed full-year 2026 guidance of $20–22 million revenue (55% growth YoY at midpoint) and $26–28 million net cash burn (10% decline YoY at midpoint), with expected cash position of $37.9 million as of September 30, 2026, providing runway into 2028.

Beyond Air reported preliminary Q3 2026 revenue of $2.3 million, representing 30% sequential growth and 27% year-over-year growth, driven by continued LungFit PH adoption. The company reaffirmed $8 million CY2026 guidance and $16–$18 million CY2027 guidance (the latter contingent on FDA approval of the second-generation system, which remains under review). All figures are preliminary and unaudited.